Corporate insider of Dynavax Technologies, Justin Burgess sold 22,371 shares of the firm’s stock worth $232,210.98. The market capitalization of Dynavax Technologies is $1.25 billion, and it has a P/E ratio of 4.95 and a beta of 1.45. The company’s fifty-day moving average price is $10.71, while its 200-day moving average price is $11.14. The biopharmaceutical company’s primary product is HEPLISAV-B, a vaccine that prevents hepatitis B virus in adults. The company’s shares opened at $9.76 on Wednesday, with corporate insiders owning 9.31% of the stock.
Yousif Capital Management LLC reduced its stake in Dynavax Technologies Co. (NASDAQ: DVAX – Get Rating) by 24.7% in the 4th quarter, according to the company’s latest 13F filing. Several other hedge funds and institutional investors have also made changes to their positions in DVAX. State Street Corp increased its position by 36.1% in the 1st quarter, while Woodline Partners LP purchased a new stake in the 2nd quarter. Moreover, Dimensional Fund Advisors LP also acquired a new stake in the 3rd quarter, and BNP Paribas Arbitrage SNC raised its position by 2,036.1% in the same quarter. Renaissance Technologies LLC increased its position by 101.2% in the 2nd quarter. The institutional investors now own 94.26% of the company’s stock.
Several analysts have recently released reports on DVAX shares. StockNews.com assumed coverage of Dynavax Technologies in a research report and set a “hold” rating. JMP Securities upped the company’s price target from $22.00 to $25.00 and gave it a “market outperform” rating, while HC Wainwright lowered the price objective from $28.00 to $27.00 and set a “buy” rating. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.33.
In addition, insider trading activities at Dynavax Technologies have been active recently.
On Monday, February 27th, Justin Burgess, the CAO of Dynavax Technologies, sold 22,371 shares of the company’s stock at an average price of $10.38, totaling $232,210.98. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. As of now, corporate insiders own 9.31% of the stock.
As of Wednesday, DVAX shares opened at $9.76. The company has a current ratio of 6.11, a quick ratio of 5.71, and a debt-to-equity ratio of 0.38. Dynavax Technologies has a market capitalization of $1.25 billion, with a P/E ratio of 4.95 and a beta of 1.45. The firm has a fifty-day moving average price of $10.71 and a 200-day moving average price of $11.14. The 12-month high and low of the stock are $17.48 and $7.26, respectively.
Dynavax Technologies Corp. is a biopharmaceutical company that develops and commercializes novel vaccines and immuno-oncology therapeutics. Its primary product is HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and above.
To keep updated on hedge funds’ holdings and insider trades of DVAX, visit HoldingsChannel.com. You can also get a daily summary of the latest news and analysts’ ratings for Dynavax Technologies and related companies by signing up for MarketBeat.com’s free daily email newsletter.
Don’t miss interesting posts on Famousbio
